- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment regimens of classical and newer taxanes
Authors
Keywords
Paclitaxel, Docetaxel, Cabazitaxel, Nab-paclitaxel, Pharmacokinetics, Therapeutic drug monitoring
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 77, Issue 2, Pages 221-233
Publisher
Springer Nature
Online
2015-11-20
DOI
10.1007/s00280-015-2893-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study
- (2014) M. Sinn et al. ANNALS OF ONCOLOGY
- Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells
- (2014) Harris Wang et al. BMC CANCER
- Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
- (2014) Sandro Pignata et al. LANCET ONCOLOGY
- Efficacy of cabazitaxel in mouse models of pediatric brain tumors
- (2014) Emily Girard et al. NEURO-ONCOLOGY
- Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours
- (2013) Pierre Fumoleau et al. BMC CANCER
- Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
- (2013) Géraldine M. Ferron et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors
- (2013) P. Vrignaud et al. CLINICAL CANCER RESEARCH
- Without Therapeutic Drug Monitoring, There Is No Personalized Cancer Care
- (2013) J H Beumer CLINICAL PHARMACOLOGY & THERAPEUTICS
- Taxanes: Old drugs, new oral formulations
- (2013) Rajni A. Jibodh et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
- (2013) Noriyuki Katsumata et al. LANCET ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring
- (2012) Markus Joerger et al. CLINICAL PHARMACOKINETICS
- Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials
- (2012) Wei-Xiang Qi et al. CURRENT MEDICAL RESEARCH AND OPINION
- Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study
- (2012) V. Diéras et al. EUROPEAN JOURNAL OF CANCER
- Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme
- (2012) Axel Heidenreich et al. EUROPEAN UROLOGY
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- The European Medicines Agency Review of Cabazitaxel (Jevtana(R)) for the Treatment of Hormone-Refractory Metastatic Prostate Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
- (2012) E. Pean et al. ONCOLOGIST
- Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis
- (2011) Ta-Chen Huang et al. CANCER TREATMENT REVIEWS
- Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study
- (2011) F. K. Engels et al. CLINICAL CANCER RESEARCH
- Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
- (2011) E S Antonarakis et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
- (2010) Ilaria Pastina et al. BMC CANCER
- nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study
- (2010) Mikhail Y Biakhov et al. Expert Opinion On Drug Safety
- A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
- (2010) Mark A. Socinski et al. Journal of Thoracic Oncology
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
- (2009) William J. Gradishar et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
- (2009) Noriyuki Katsumata et al. LANCET
- CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance
- (2008) V G Martinez et al. BRITISH JOURNAL OF CANCER
- Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer
- (2008) Edgardo Rivera et al. CANCER
- Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer
- (2008) Satoru Tanaka et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer
- (2008) Chandra P. Belani et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
- (2008) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started